A minimally invasive treatment that delivers cancer-killing radiation directly to tumors shows promise in treating breast cancer that has spread to the liver when no other treatment options remain.

Aug. 17 was the 10th anniversary of 59-year-old Dal Anderson’s carcinoid cancer diagnosis. He commemorated the occasion by writing his cancer a letter. After all, there have been some perks, he says.

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed ...

Survival of patients treated with SIR-Spheres more than double that of patients who received best supportive care, benefit rivals that found with new biological agents, authors note The results of a ...

March 29, 2012 (Orlando, Florida) — Results of the largest study to date assessing the efficacy of radioembolization with yttrium-90 microspheres in the treatment of unresectable hepatic tumors have ...

Bleeding events and eligibility requirements in studies evaluating an antiangiogenic agent in hepatocellular carcinoma (HCC). Background: Few effective treatments exist for unresectable hepatic ...

Hackensack Meridian Health Bayshore Medical Center now offers Y-90 radioembolization, an advanced and minimally invasive method to treat liver tumors without surgery. This procedure is used to treat ...

The majority of patients with advanced colorectal cancer die from hepatic metastases caused by disease progression; therefore, several novel technologies are in clinical development to potentially ...

A team of physicians from the Baylor College of Medicine and the Texas Children’s Cancer Center’s Pediatric Liver Tumor Program have begun using a state-of-the-art treatment known as transarterial ...

Radioembolization is a generally painless procedure for liver cancer that directly targets the blood supply to the tumor site. Approximately 70% to 95% of patients will experience improvements in ...

Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The ...

Background. A 58-year-old white man who was being followed by his hepatologist for nonalcoholic steatohepatitis-related liver cirrhosis and portal hypertension and who had been found to have a ...